Dallas, Texas (PRWEB) May 03, 2013
This market report summarizes the results of global web-based benchmarking survey on outsourced ion channel testing carried out in April 2013. The full report provides the data, details of the breakdown of the responses for each question, its segmentation and the estimates for the future (2015). It also highlights some interesting differences between the survey groups. The main objectives are to comprehensively document current use of and potential interest in outsourcing ion channel primary screening, selectivity profiling and safety liability testing. The survey also investigated access to and future purchasing of stably transfected ion channel cell lines. Equal emphasis was given to soliciting opinion from Pharma, Biotech and Academic Research segments, mainly in North America and Europe.
The survey looked at the following aspects of outsourced ion channel testing - http://www.reportsnreports.com/reports/239426-outsourced-ion-channel-testing-trends-2013.html, as practiced to date (2013) and in some cases as predicted for the future (2015):
1. Current targeting of ion channels as therapeutic targets using primary screening;
2. Number of on-going screening programs with ion channels as a therapeutic target;
3. Preferred and alternative primary screening platform technology;
4. Current outsourcing of ion channel primary screening;
5. Why some respondents have you not outsourced ion channel primary screening to date;
6. Current level of interest in outsourcing ion channel primary screening;
7. Primary screening platforms respondents would most like to access at a fee-for-service service provider;
8. Primary screening services respondents most envision accessing and price points for those services;
9. Stage where respondents are most interested in outsourcing ion channel selectivity profiling;
10. Preferred selection of assays when deciding on ion channel selectivity profiling;
11. Ion channel panels of most interest when considering selectivity profiling;
12. Technology platforms respondents most want to access at a fee-for-service service provider for selectivity profiling;
13. With respect to patch clamping data the preferred vendor’s platform; current level of interest in outsourcing ion channel selectivity profiling;
14. Current outsourcing of ion channel selectivity profiling;
15. What motivates selection of an ion channel selectivity profiling service provider;
16. Selectivity profiling services respondents most envision accessing and price points for those services;
17. Aspects of ion channel safety liability testing that are outsourced;
18. Current level of interest in outsourcing safety liability testing;
19. Current outsourcing of ion channel safety liability testing;
20. What motivates selection of an ion channel safety liability testing service provider;
21. Outsourcing budget for all ion channel testing done at fee-for-service labs and its breakdown into service categories;
22. Type of service providers most interested in accessing for ion channel outsourcing;
23. Importance of different ion channel testing services offered;
24. Preferred fee-for-service providers of ion channel primary screening, ion channel selectivity profiling and ion channel safety liability testing;
25. Most trusted and most used ion channel services providers;
26. Respondents with access to stably transfected ion channel cell lines in house;
27. Source of stably transfected cell lines used; plans to purchase any stably transfected cell lines over the next few years;
28. Budget allocation to purchase stably transfected cell lines;
29. And any unmet needs in outsourced ion channel testing.
Survey responses were geographically split: 50% North America; 38% Europe; 9% Asia (excluding Japan); and 3% Japan. Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was reanalyzed after sub-division into the following 5 survey groups: 1) Large Pharma; 2) Other Screening Labs; 3) Academic Research; 4) Europe; and 5) North America. 55% of respondents were investigating/targeting ion channels as therapeutic targets using primary screening, with a median of 4 screening programs being undertaken today (2013). The current (2013) level of interest in outsourcing ion channel primary screening was low and most of this was small-scale (10-100 compounds screened). The median price point for accessing this outsourced primary screening was $1-$2 maximum price per data point. Of those respondents interested/involved in outsourcing primary screening a median of 2 programs per year were outsourced today (2013). The preferred platform accessed was automated patch-clamp (APC). Most respondents want to outsource selectivity profiling after secondary/counter screening. A pain-inflammation channel panel was most wanted panel for selectivity profiling. After manual patch clamp the preferred vendor’s platform for patch clamping data was Sophion QPatch HT.
The following scenarios were envisaged for outsourced selectivity profiling services; 1) selection by target; 2) median 6 to 10 channels per profile; 3) median 6 to 10 compounds per profile; and 4) median $1-$2 maximum price per data point price. hERG ion channel assays were the aspect of ion channel safety liability testing respondents most want to outsource today (2013).
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=239426.
Explore more reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/.
ReportsnReports.com (http://www.reportsnreports.com/) is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets.